"I've been working international fugitives with the FBI about 26 years… we've arrested a lot of bad guys," says FBI Special Agent Phil Torsney. "This is a once-in-a-lifetime case…and it was certainly ...
CLEARFIELD, PA and STROUDSBURG, PA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- CNB Financial Corporation (Nasdaq: CCNE) (“CNB”), parent company of CNB Bank, and ESSA ...
States are using new indicators to measure and support student and school performance under the Every Student Succeeds Act. For years, federally driven school classification systems focused almost ...
When President Barack Obama signed the Every Student Succeeds Act on Dec. 10, 2015, he called it a “Christmas miracle.” The law, which replaced the much-criticized No Child Left Behind Act, ...
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /CNW/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered ...
After more than a year of preparation, the Every Student Succeeds Act is on the verge of hitting classrooms nationwide. And nearly all states have now laid out their blueprints for how they intend to ...
The most recent version of the Elementary and Secondary Education Act, called the Every Student Succeeds Act (ESSA), included in its design an attempt to scale back some of the burdensome federal ...
In December 2015, Congress passed the Every Student Succeeds Act (ESSA) amid strong bipartisan support. The House passed the bill by 359–64, and seven days later the Senate passed the bill 85–12; ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...
ESSA Pharma (NASDAQ:EPIX) fell above 18% premarket on Wednesday after the company revised terms of its merger with biotech firm XenoTherapeutics, lowering expected shareholder payout due to potential ...
ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enzalutamide versus enzalutamide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback